REG - Kromek Group PLC - £1.7m contract win under UK Government Framework

KromekAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250721:nRSU7927Ra&default-theme=true

RNS Number : 7927R  Kromek Group PLC  21 July 2025

21 July 2025

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek wins £1.7m contract under UK Government Framework

First contract award under the UK Government's Radiological Nuclear Detection
Framework

 

Kromek (AIM: KMK), a global detection company delivering best-in-class
solutions for the advanced imaging and CBRN detection markets, is pleased to
announce that it has received its first contract, worth £1.7m, under the UK
Government's Radiological Nuclear Detection Framework (the "Framework") for
the procurement of radiological nuclear detection equipment and supporting
services for the Home Office.

 

As noted in the Group's announcement of 23 September 2024, Kromek is
pre-qualified to receive orders under three Framework categories, covering the
supply of handheld, wearable and large volume static radiation detectors. The
Group's new contract, which is part of the first procurement round under the
four-year Framework, is for the supply of Kromek's D3S-ID wearable radiation
detector and ongoing training and product maintenance. The total value for
this contract is £1.7m, of which a significant majority is scheduled to be
received in the Group's current financial year and which will contribute
towards the expected revenue growth in the CBRN Detection segment.

 

Arnab Basu, CEO of Kromek, said: "We're proud to win our first contract under
the UK Government framework for radiological and nuclear detection equipment.
As one of the few pre-approved suppliers, we are uniquely positioned to
support the Home Office's mission to strengthen national security and to
secure further strategic orders. This contract affirms our leadership in the
sector and highlights the significant growth potential unlocked by our
selection for this critical framework".

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Claire Burgess, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

 In CBRN detection, the Group provides nuclear radiation detection solutions
to the global homeland defence and security market. Kromek's compact,
handheld, high-performance radiation detectors, based on advanced
scintillation and solid-state readout technology, are primarily used to
protect critical infrastructure, events, personnel and urban environments from
the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTQBLFLEDLEBBE